Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenicriviroc DDI with Statins, Digoxin, and Caffeine
NCT02685462Phase 1Completed
- Sponsor
- Tobira Therapeutics
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH) and human immunodeficiency virus infection (HIV) (3 arms), sponsored by Tobira Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 13, Minimum Plasma Concentration at Day 13 and 1 more. Started Jan 2016; status: completed.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02685462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685462.